Angiogenesis inhibitor

Source: Wikipedia, the free encyclopedia.
(Redirected from
Anti-angiogenesis
)

An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (

pharmaceutical drugs or diet
.

While angiogenesis is a critical part of

tumors. Thus angiogenesis inhibitors have been closely studied for possible cancer treatment. Angiogenesis inhibitors were once thought to have potential as a "silver bullet" treatment applicable to many types of cancer, but the limitations of anti-angiogenic therapy have been shown in practice.[1] Currently, angiogenesis inhibitors are recognized for their improvement of cancer immunotherapy [2][3] by overcoming endothelial cell anergy. Angiogenesis inhibitors are also used to effectively treat macular degeneration in the eye, and other diseases that involve a proliferation of blood vessels.[4][5][6]

Mechanism of action

When a tumor stimulates the growth of new vessels, it is said to have undergone an 'angiogenic switch'. The principal stimulus for this angiogenic switch appears to be oxygen deprivation, although other stimuli such as inflammation, oncogenic mutations and mechanical stress may also play a role. The angiogenic switch leads to tumor expression of pro-angiogenic factors and increased tumor vascularization.

integrins, are critical to the attachment and migration of endothelial cells to the extracellular matrix.[7]

VEGF pathway inhibition

Inhibiting angiogenesis requires treatment with anti-angiogenic factors, or drugs which reduce the production of pro-angiogenic factors, prevent them binding to their receptors or block their actions. Inhibition of the VEGF pathway has become the focus of angiogenesis research, as approximately 60% of malignant tumors express high concentrations of VEGF. Strategies to inhibit the VEGF pathway include

tyrosine kinase inhibitors.[7][9] The most widely used VEGF pathway inhibitor on the market today is Bevacizumab.[citation needed] Bevacizumab binds to VEGF and inhibits it from binding to VEGF receptors.[10]

Endogenous regulation

Angiogenesis is regulated by the activity of endogenous stimulators and inhibitors. Endogenous inhibitors, found in the body naturally, are involved in the day-to-day process of regulating blood vessel formation. Endogenous inhibitors are often derived from the extracellular matrix or basement membrane proteins and function by interfering with

endothelial cell formation and migration, endothelial tube morphogenesis, and down-regulation
of genes expressed in endothelial cells.

During tumor growth, the action of angiogenesis stimulators surpasses the control of angiogenesis inhibitors, allowing for unregulated or less regulated blood vessel growth and formation.

cancer therapy because they are less toxic and less likely to lead to drug resistance than some exogenous inhibitors.[7][9] However, the therapeutic use of endogenous inhibitors has disadvantages. In animal studies, high doses of inhibitors were required to prevent tumor growth and the use of endogenous inhibitors would likely be long-term.[11]

Inhibitors Mechanism
soluble
NRP-1
decoy receptors[12] for VEGF-B and PIGF
Angiopoietin 2
antagonist of angiopoietin 1
TSP-1 and TSP-2 inhibit cell migration, cell proliferation, cell adhesion and survival of endothelial cells
angiostatin and related molecules inhibit cell proliferation and induce apoptosis of endothelial cells
endostatin inhibit cell migration, cell proliferation and survival of endothelial cells
vasostatin, calreticulin
inhibit cell proliferation of endothelial cells
platelet factor-4
inhibits binding of
bFGF and VEGF
TIMP and CDAI
inhibit cell migration of endothelial cells
ADAMTS1 and ADAMTS8
-β and , CXCL10, IL-4, -12 and -18
inhibit cell migration of endothelial cells, downregulate bFGF
antithrombin III
fragment
inhibit cell proliferation of endothelial cells
prolactin VEGF
VEGI
affects cell proliferation of endothelial cells
SPARC inhibit binding and activity of VEGF
osteopontin inhibit integrin signalling
maspin inhibits
proteases
canstatin (a fragment of
COL4A2
)
inhibits endothelial cell migration, induces apoptosis[13]
proliferin-related protein mannose 6-phosphate binding lysosomal protein[14]

A recent method for the delivery of anti-angiogenesis factors to tumor regions in cancer patients uses

Bifidobacteria and Salmonella by adding genes for anti-angiogenic factors such as endostatin or IP10 chemokine and removing any harmful virulence genes. A target can also be added to the outside of the bacteria so that they are sent to the correct organ in the body. The bacteria can then be injected into the patient and they will locate themselves to the tumor site, where they release a continual supply of the desired drugs in the vicinity of a growing cancer mass, preventing it from being able to gain access to oxygen and ultimately starving the cancer cells.[15] This method has been shown to work both in vitro and in vivo in mice models, with very promising results.[16] It is expected that this method will become commonplace for treatment of various cancer types in humans in the future.[citation needed
]

Exogenous regulation

Diet

Some common components of human diets also act as mild angiogenesis inhibitors and have therefore been proposed for angioprevention, the prevention of metastasis through the inhibition of angiogenesis. In particular, the following foods contain significant inhibitors and have been suggested as part of a healthy diet for this and other benefits:

Drugs

Research and development in this field has been driven largely by the desire to find better cancer treatments. Tumors cannot grow larger than 2mm without angiogenesis. By stopping the growth of blood vessels, scientists hope to cut the means by which tumors can nourish themselves and thus

metastasize
.

In addition to their use as anti-cancer drugs, angiogenesis inhibitors are being investigated for their use as

vitreous humor of the eye.[33]

Overview

Inhibitors Mechanism
bevacizumab (Avastin) VEGF
itraconazole inhibits
VEGFR phosphorylation, glycosylation, mTOR signaling, endothelial cell proliferation, cell migration, lumen formation, and tumor associated angiogenesis.[34][35][36]
carboxyamidotriazole Methionine aminopeptidase 2 inhibitors,[37] inhibit cell proliferation and cell migration of endothelial cells
TNP-470 (an analog of fumagillin)
CM101 activate immune system
IFN-α
downregulate angiogenesis stimulators and inhibit cell migration of endothelial cells
IL-12 stimulate angiogenesis inhibitor formation
platelet factor-4
inhibits binding of angiogenesis stimulators
suramin
SU5416
thrombospondin
VEGFR antagonists
angiostatic steroids + heparin inhibit basement membrane degradation
Cartilage-Derived Angiogenesis Inhibitory Factor
matrix metalloproteinase inhibitors
angiostatin inhibit cell proliferation and induce apoptosis of endothelial cells
endostatin inhibit cell migration, cell proliferation and survival of endothelial cells
2-methoxyestradiol
inhibit cell proliferation and cell migration and induce apoptosis of endothelial cells
tecogalan inhibit cell proliferation of endothelial cells
tetrathiomolybdate copper chelation which inhibits blood vessel growth
thalidomide inhibit cell proliferation of endothelial cells
thrombospondin inhibit cell migration, cell proliferation, cell adhesion and survival of endothelial cells
prolactin VEGF
αVβ3
inhibitors
induce apoptosis of endothelial cells
linomide
inhibit cell migration of endothelial cells
ramucirumab inhibition of VEGFR2[38]
tasquinimod Unknown[39]
ranibizumab VEGF[40]
sorafenib (Nexavar) inhibit kinases
sunitinib (Sutent)
pazopanib (Votrient)
everolimus (Afinitor)
Mechanism of action of angiogenesis inhibitors. Bevacizumab binds to VEGF inhibiting its ability to bind to and activate VEGF receptors. Sunitinib and Sorafenib inhibit VEGF receptors. Sorafenib also acts downstream.

Bevacizumab

Through binding to

VEGFR and other VEGF receptors in endothelial cells, VEGF can trigger multiple cellular responses like promoting cell survival, preventing apoptosis, and remodeling cytoskeleton, all of which promote angiogenesis. Bevacizumab (brand name Avastin) traps VEGF in the blood, lowering the binding of VEGF to its receptors. This results in reduced activation of the angiogenesis pathway, thus inhibiting new blood vessel formation in tumors.[11]

After a series of

Avastin was approved by the FDA, becoming the first commercially available anti-angiogenesis drug. FDA approval of Avastin for breast cancer treatment was later revoked on November 18, 2011.[41]

Thalidomide

Despite the therapeutic potential of anti-angiogenesis drugs, they can also be harmful when used inappropriately.

deformities, most notably phocomelia, as a consequence of thalidomide use.[42]

Cannabinoids

According to a study published in the August 15, 2004 issue of the journal Cancer Research,

marijuana, restrict the sprouting of blood vessels to gliomas (brain tumors) implanted under the skin of mice, by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).[43]

General side effects of drugs

Bleeding

Bleeding is one of the most difficult side effects to manage; this complication is somewhat inherent to the effectiveness of the drug. Bevacizumab has been shown to be the drug most likely to cause bleeding complications.[citation needed] While the mechanisms of bleeding induced by anti-VEGF agents are complicated and not yet totally understood, the most accepted hypothesis is that VEGF could promote endothelial cell survival and integrity in the adult vasculature and its inhibition may decrease capacity for renewal of damaged endothelial cells.[44]

Increased blood pressure

In a study done by ML Maitland, a mean blood pressure increase of 8.2 mm Hg systolic and 6.5 mm Hg diastolic was reported in the first 24 hours after the first treatment with sorafenib, a VEGF pathway inhibitor.[45][non-primary source needed]

Less common side effects

Because these drugs act on parts of the blood and blood vessels, they tend to have side effects that affect these processes. Aside from problems with hemorrhage and hypertension, less common side effects of these drugs include dry, itchy skin, hand-foot syndrome (tender, thickened areas on the skin, sometimes with blisters on palms and soles), diarrhea, fatigue, and low blood counts. Angiogenesis inhibitors can also interfere with wound healing and cause cuts to re-open or bleed. Rarely, perforations (holes) in the intestines can occur.[44]

See also

References

  1. PMID 19360048
    .
  2. ^ Fukumura, D., et al., Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol, 2018. 15(5): p. 325-340. doi: 10.1038/nrclinonc.2018.29
  3. ^ Huinen, Z., et al., Anti-angiogenic agents - overcoming tumor endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol., 2021. 18(8): p. 527-540. doi: 10.1038/s41571-021-00496-y
  4. ^ Dudley, A.C. & Griffioen, A.W., Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis, 2023. doi: 10.1007/s10456-023-09876-7
  5. ^ Cancer.com [homepage on the Internet]. National Cancer Institute at the National Institutes of Health; 2011 [cited 18 March 2014]. Available from: "Angiogenesis Inhibitors". Archived from the original on 2015-02-08. Retrieved 2022-05-09.
  6. PMID 15947805
    .
  7. ^ .
  8. , retrieved 2022-07-13
  9. ^ .
  10. .
  11. ^ .
  12. ^ Hugo H. Marti, "Vascular Endothelial Growth Factor", Madame Curie Bioscience Database, Landes Bioscience, retrieved January 25, 2012
  13. PMID 10625665
    .
  14. .
  15. ^ Gardlik, R., Behuliak, M., Palffy, R., Celec, P., & Li, C. J. (2011). Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene therapy, 18(5), 425-431.
  16. ^ Xu, Y. F., Zhu, L. P., Hu, B., Fu, G. F., Zhang, H. Y., Wang, J. J., & Xu, G. X. (2007). A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer gene therapy, 14(2), 151-157.
  17. PMID 16969510
    .
  18. .
  19. .
  20. .
  21. .
  22. .
  23. .
  24. .
  25. .
  26. .
  27. .
  28. .
  29. ^ a b Smith, Roderick. Antiangiogenic Substances in Blackberries, Licorice May Aid Cancer Prevention. Archived 2010-02-14 at the Wayback Machine The Angiogenesis Foundation. 6 May 2009.[unreliable medical source?]
  30. S2CID 968172
    .
  31. .
  32. .
  33. .
  34. .
  35. .
  36. .
  37. .
  38. ^ Ramucirumab (Cyramza) package insert
  39. PMID 21717904
    . Retrieved 9 May 2022.
  40. .
  41. ^ FDA News Release on Avastin, retrieved 2014-04-15
  42. PMID 21507989
    .
  43. .
  44. ^ .
  45. .

Further reading

External links